Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9039
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHarjianti, Tutik-
dc.contributor.authorBenyamin, Fachrudin-
dc.contributor.authorMinhajat, Rahmawati-
dc.contributor.authorSaleh, Sahyuddin-
dc.contributor.authorBayu, Dimas-
dc.contributor.authorPababbari, Wahyudi-
dc.date.accessioned2024-12-14T06:35:21Z-
dc.date.available2024-12-14T06:35:21Z-
dc.date.issued2023-07-01-
dc.identifier.issn2338-2732-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/9039-
dc.description.abstractABSTRACT Management of chronic myeloid leukemia (CML) in patients who are infected with COVID-19 is a challenging task due to disease-related or treatment-related factors that place such patients at a higher risk of complications. However, a low-infectivity-rate mechanism has been proposed by some researchers. In CML patients with COVID-19 infection, the most important treatment-related factor involves tyrosine kinase inhibitors (TKIs). In this case report, six patients with chronic-phase CML who experienced COVID-19 of mild–moderate severity all continued to receive TKI treatment for CML concurrently with COVID-19 treatment. All patients fully recovered. In the present study, we also review four other cases of COVID-19 infection in CML patients. Outcomes for TKI-treated CML patients who contract COVID-19 are influenced by many factors. Tyrosine kinase inhibitor therapy may benefit CML patients due to its antiviral effect, but the interaction between TKIs and drugs used for COVID-19 treatment requires careful monitoring. An individual approach is needed in every case. Keywords : Chronic Myeloid Leukemia, Tyrosine Kinase Inhibitor, COVID-19, Case Reporten_US
dc.language.isoenen_US
dc.publisherPerhimpunan Dokter Spesialis Penyakit dalam Indonesiaen_US
dc.subjectChronic Myeloid Leukemia,en_US
dc.subjectTyrosine Kinase Inhibitor,en_US
dc.subjectCOVID-19,en_US
dc.subjectCase Reporten_US
dc.titleCOVID-19 Infection in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor in Makassar, Indonesia: A Six-Case Report and Literature Reviewen_US
dc.typeArticleen_US
Appears in Collections:VOL 55 NO 3 2023

Files in This Item:
File Description SizeFormat 
332-338.pdf366.28 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.